Colchicine-Resistant Familial Mediterranean Fever: Choosing the IL-1 Blocker
Colchicine has capped her fever days but not the inflammation running underneath them. Two IL-1 blockers both work — the real argument is about dosing rhythm, not mechanism.
Diagnosed with familial Mediterranean fever at age nine and genotyped as homozygous for MEFV M694V — the genotype the Tel Hashomer-era cohort literature and the later Turkish FMF registries consistently tie to a more severe phenotype and the highest reported amyloidosis risk — Elif K. is now 26, a pastry chef who has kept a 4:30 a.m. bakery schedule for six years and has no intention of giving it up. Colchicine controlled her attacks reasonably well through adolescence; over the past eighteen months, despite being titrated to 2mg daily, the ceiling her gastrointestinal tolerance allows, she has continued to have monthly one- to two-day attacks of fever, peritonitis-like abdominal pain, and a large-joint arthritis that has twice kept her off her feet during a shift.
The more consequential problem is not the attacks themselves but what her labs show between them: a serum amyloid A that never fully normalizes, running 40-60 mg/L in her best weeks rather than the low single digits a controlled patient should show. That persistent elevation is not a symptom she can feel — it is the actual mechanism by which AA amyloidosis eventually damages the kidney, and its presence despite maximal colchicine is the formal definition of colchicine resistance the team is now treating, not a softer failure-to-fully-control. A same-day urine protein-to-creatinine ratio remains normal, meaning the window to prevent renal amyloid deposition, not merely treat it, is still open. Anakinra and canakinumab both block that axis, and either would plausibly bring the number down; the argument is over dosing rhythm, not mechanism. But her own chart has already answered the question the rhythm argument rests on. Ten years of documented, uninterrupted daily colchicine taken around a 4:30 a.m. shift is not a hypothetical about whether she could sustain a daily injection — it is the answer, and it means a monthly agent has to earn its place on the SAA evidence rather than on an assumption about her schedule.
Choosing between two drugs that both work
I want to start with canakinumab, and I want to be specific about why: the CLUSTER trial randomized colchicine-resistant FMF patients against placebo and showed canakinumab controlled clinical attacks and drove SAA down toward normal — the exact biomarker sitting elevated in her chart right now. That is not a comparison of two reasonable anti-IL-1 options in the abstract; it is trial-level evidence that this specific drug closes the exact gap she has.
A once-monthly subcutaneous injection is also, practically, the better fit for someone managing a bakery schedule around a chronic disease — one appointment with herself a month, rather than a daily ritual she has to protect from an early alarm and tired hands.
I don't dispute the CLUSTER data, and I'm not arguing anakinra is more effective — the observational evidence for anakinra in colchicine-resistant FMF is real but it isn't a placebo-controlled trial, and I'll say that plainly rather than oversell it.
What I'd weigh instead is anakinra's short half-life, which is a property worth choosing for its own sake in a drug she may be on for years: if a flare breaks through, the dose can be pushed up the same day; if she becomes pregnant, or develops a site reaction severe enough to need a different plan, the drug is largely cleared within a day rather than committing her to a month of exposure she can no longer easily undo.
Both of you are arguing from the drug outward. I'd rather argue from her. She has ten years of documented, reliable daily colchicine dosing around exactly this shift — that's not a hypothetical adherence risk, it's a demonstrated pattern more specific to her than either drug's general convenience profile.
That doesn't settle which drug is pharmacologically better, and I'm not claiming it does. It just means the adherence argument for canakinumab's monthly schedule is thinner than it sounds — she has already proven she can do daily. The stronger reason to start with canakinumab is the SAA data specifically, not a convenience assumption about a schedule she's never actually struggled with.
Canakinumab was started at the standard dose, with a repeat SAA and urine protein-to-creatinine ratio planned at three months rather than assumed normal on symptom improvement alone — the team's explicit acknowledgment that clinical attack frequency and the amyloidosis-relevant biomarker do not necessarily move together on the same timeline.
Not agreed, and left as an open contingency rather than resolved: if SAA has not meaningfully fallen by three months despite good injection-site technique and confirmed dosing, the Clinical Pharmacologist's argument for anakinra's reversibility and dose-titration flexibility becomes the stronger case, and the Rheumatologist agreed to revisit the decision on that specific trigger rather than defend canakinumab indefinitely on the strength of the trial alone.